Related Experiment Video
Updated: Jun 4, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Primary Care Screening for Nonalcoholic Fatty Liver Disease Among People With HIV in the United States: A Real-World
Jennifer C Price1, Kyoko Hirose, Naga Chalasani
1Jennifer C. Price, MD, PhD, is a Professor, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA. Kyoko Hirose, BA, is a Research Coordinator, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA. Naga Chalasani, MD, is a Professor, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Holly Crandall, RN, BSN, CCRP, is a Project Manager, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Sonya Heath, MD, is a Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. Rohit Loomba, MD MHSc, is a Professor, Division of Gastroenterology and Hepatology, University of California, San Diego, California, USA. Susanna Naggie, MD, is a Professor, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA. Richard K. Sterling, MD, MSc, is a Professor, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA. Mark Sulkowski, MD, is a Professor, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Laura Wilson, ScM, is a Senior Research Associate, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. Jordan E. Lake, MD, MSc, is an Associate Professor, Division of Infectious Disease, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in people with HIV (PWH) and increases the risk of hepatic fibrosis and hepatocellular carcinoma. We sent an online survey to providers of the American Academy of HIV Medicine. Of respondents ( n = 214, 8% response rate), 65% reported screening for NAFLD in PWH, with 28% routinely screening all patients. Most respondents refer patients to hepatology if workup suggests another coexisting liver disease or cirrhosis, with the primary goals of referral being additional diagnostic testing (60%) or specific treatments (75%). The most common barriers to screening were feeling unsure of what tests to order (28%) and how to conclusively diagnose NAFLD (29%). Most respondents were interested in society guidelines (73%) and NAFLD education for patients (57%) and providers (55%). Our findings support the development of NAFLD clinical practice guidelines for HIV providers and the inclusion of PWH in clinical trials of novel agents.
More Related Videos
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Chronic Pancreatitis II: Collaborative Care
Assessment: